A Study of R1507 in Patients With Recurrent or Refractory Sarcoma

A Study of R1507 in Patients With Recurrent or Refractory Sarcoma

Sarcoma

Does not allow GIST

2

Start Date 07/01/2008

Age of Trial (yrs) 15.8

Gleevec-resistant

IGF1R inhibitor

Block related tumor signal paths

GIST not specified. GIST patient enrollment unknown.

SARC011 NO21157

Hoffman-La Roche, SARC

Contact: Please reference Study ID Number: NO21157 973-235-5000 Contact: Please reference Study ID Number: SARC011 734-930 7600 (FOR US ONLY)

734-930 7600

Intravenous

NOTE: Per SARC, this trial does not allow GIST patients.

This trial specifies several sarcomas but not specifically GIST. As of 5/18/09 all previously opened sites are active but not recruiting except for Paris France.
Trials of IGF1R inhibitors such as R1507, would be most appropriate for patients with wild-type GIST and/or pediatric GIST.